

TABLE OF CONTENTS

THESIS PROPOSAL	1
THESIS APPROVAL	2
STATEMENT	3
PREFACE	4
TABLE OF CONTENTS	6
LIST OF FIGURES	10
LIST OF TABLES	11
LIST OF ABBREVIATIONS	14
ABSTRACT	15
CHAPTER I: BACKGROUND	16
1.1. INTRODUCTION.....	16
1.2. PROBLEM FORMULATION.....	18
1.2.1. HOW EFFECTIVE ARE THE FIVE NON-HYDROQUINONE PRODUCTS IN TREATING UVB-INDUCED ERYTHEMA?.....	18
1.2.2. ARE THERE ANY SIGNIFICANT DIFFERENCES BETWEEN THE PRODUCTS IN REDUCING UVB-INDUCED ERYTHEMA?.....	18
1.2.3. WHICH PRODUCT IS THE MOST EFFECTIVE IN REDUCING UVB-INDUCED ERYTHEMA?	18
1.2.4. HOW EFFECTIVE ARE THE FIVE NON-HYDROQUINONE PRODUCTS IN TREATING UVB-INDUCED MELANODERMA?	18
1.2.5. ARE THERE ANY SIGNIFICANT DIFFERENCES BETWEEN THE PRODUCTS IN REDUCING UVB-INDUCED MELANODERMA?.....	18
1.2.6. WHICH PRODUCT IS THE MOST EFFECTIVE IN REDUCING UVB-INDUCED MELANODERMA?.....	18
1.3. OBJECTIVES	18
1.4. RESEARCH AUTHENTICITY.....	20
1.5. RESEARCH BENEFIT.....	24

CHAPTER II: LITERATURE REVIEW	25
2.1. LITERATURE REVIEW.....	25
2.1.1. <i>SKIN STRUCTURE AND LAYERS</i>	25
2.1.2. <i>ERYTHEMA AND HYPERPIGMENTATION</i>	31
2.1.3. <i>ULTRAVIOLET RADIATION</i>	34
2.1.4. <i>CURRENT TREATMENTS FOR POST-INFLAMMATORY HYPERPIGMENTATION</i>	37
2.1.5. <i>PRODUCT A</i>	39
2.1.5.1. <i>ARBUTIN 2%</i>	39
2.1.5.2. <i>α-LIPOIC ACID (ALA)</i>	40
2.1.5.3. <i>α-HYDROXY ACID (AHA)</i>	41
2.1.5.4. <i>SODIUM ASCORBYL PHOSPHATE (SAP)</i>	42
2.1.6. <i>PRODUCT B</i>	43
2.1.6.1. <i>L-ASCORBIC ACID 2-GLUCOSIDE (LAA-2G) 2%</i>	43
2.1.7. <i>PRODUCT C</i>	45
2.1.7.1. <i>ADAPALENE 0.1%</i>	45
2.1.8. <i>PRODUCT D</i>	46
2.1.8.1. <i>LACTIC ACID 4%</i>	46
2.1.8.2. <i>KOJIC ACID</i>	47
2.1.8.3. <i>RUMEX OCCIDENTALIS EXTRACT</i>	48
2.1.9. <i>PRODUCT E</i>	48
2.1.9.1. <i>RETINOIC ACID 0.025%</i>	48
2.1.10. <i>MEXAMETER® BY COURAGE-KHAZAKA</i>	49
2.3. CONCEPTUAL FRAMEWORK.....	51
2.4. HYPOTHESIS	52
CHAPTER III: METHOD	53
3.1. DESIGN	53
3.1.1. <i>RESEARCH DESIGN</i>	53
3.1.2. <i>RESEARCH PLACE</i>	53
3.1.3. <i>RESEARCH PERIOD</i>	53

3.2.	SUBJECT	53
3.2.1.	<i>SUBJECT NUMBER ESTIMATION</i>	53
3.2.2.	<i>INCLUSION AND EXCLUSION CRITERIA</i>	54
3.3.	TOOLS AND MATERIALS.....	54
3.4.	IN RESEARCH METHOD	55
3.5.	VARIABLE AND DATA	58
3.6.	OPERATIONAL DEFINITION	58
3.7.	RESULT ANALYSIS	58
3.8.	SCHEDULE OF THE STUDY	60
3.9.	COST OF THE STUDY	60
CHAPTER IV: RESULTS AND DISCUSSION		61
4.1.	RESULTS	61
4.1.1.	ERYTHEMA INDEX CHANGES AMONG NON-HYDROQUINONE WHITENING PRODUCTS AT WEEK 0 AND WEEK 2 USING MEXAMETER®	61
4.1.2.	ERYTHEMA INDEX CHANGES AMONG NON-HYDROQUINONE WHITENING PRODUCTS AT WEEK 2 AND WEEK 4 USING MEXAMETER®	64
4.1.3.	MELANODERMA INDEX CHANGES AMONG NON-HYDROQUINONE WHITENING PRODUCTS AT WEEK 0 AND WEEK 2 USING MEXAMETER®	67
4.1.4.	MELANODERMA INDEX CHANGES AMONG NON-HYDROQUINONE WHITENING PRODUCTS AT WEEK 2 AND WEEK 4 USING MEXAMETER®	70
4.1.5.	COMPARING THE EFFECTIVENESS OF NON-HYDROQUINONE WHITENING PRODUCTS ON ERYTHEMA INDEX USING MEXAMETER®	73
4.1.6.	COMPARING THE EFFECTIVENESS OF NON-HYDROQUINONE WHITENING PRODUCTS ON MELANODERMA INDEX USING MEXAMETER®	79



4.2.	DISCUSSION	83
CHAPTER V: CONCLUSIONS AND RECOMMENDATIONS		92
5.1.	CONCLUSION	92
5.2.	RECOMMENDATIONS	93
REFERENCES		95
APPENDICES		109